CR7611A - Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona - Google Patents

Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona

Info

Publication number
CR7611A
CR7611A CR7611A CR7611A CR7611A CR 7611 A CR7611 A CR 7611A CR 7611 A CR7611 A CR 7611A CR 7611 A CR7611 A CR 7611A CR 7611 A CR7611 A CR 7611A
Authority
CR
Costa Rica
Prior art keywords
cilotiocarbamate
hormone
derivatives
treatment
conditions related
Prior art date
Application number
CR7611A
Other languages
English (en)
Inventor
Fensome Andrew
Grubb Gary
Harrison Diane
Craig Winneker Richard
Zhang Puwen
Curtis Kern Jeffrey
Anthony Terefenko Eugene
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of CR7611A publication Critical patent/CR7611A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion proporciona metodos para inducir la anticoncepcion que incluye la administracion a una mujer de una composicion que contiene un compuesto de la formula I, formula II, o tautomeros de los mismos, en un regimen que involucra la administracion de uno o mas de un modulador del receptor de estrogeno selectivo.
CR7611A 2002-06-25 2004-12-08 Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona CR7611A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39187102P 2002-06-25 2002-06-25

Publications (1)

Publication Number Publication Date
CR7611A true CR7611A (es) 2006-05-30

Family

ID=30000766

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7611A CR7611A (es) 2002-06-25 2004-12-08 Uso de derivados de cilotiocarbamato en tratamiento de condiciones relacionadas con la hormona

Country Status (19)

Country Link
US (1) US7192956B2 (es)
EP (1) EP1515725A4 (es)
JP (1) JP2005535624A (es)
KR (1) KR20050013247A (es)
CN (1) CN1662241A (es)
AR (1) AR040333A1 (es)
AU (1) AU2003247608A1 (es)
BR (1) BR0312024A (es)
CA (1) CA2489847A1 (es)
CO (1) CO5680438A2 (es)
CR (1) CR7611A (es)
EC (1) ECSP055576A (es)
IL (1) IL165396A0 (es)
MX (1) MXPA04012421A (es)
NO (1) NO20045216L (es)
RU (1) RU2005101638A (es)
TW (1) TW200404548A (es)
WO (1) WO2004000801A2 (es)
ZA (1) ZA200410411B (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6391907B1 (en) * 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
TW200407124A (en) * 2002-06-25 2004-05-16 Wyeth Corp Use of thio-oxindole derivatives in treatment of hormone-related conditions
US20040248989A1 (en) 2003-06-05 2004-12-09 Risto Santti Method for the treatment or prevention of lower urinary tract symptoms
CA2561014C (en) * 2004-04-08 2013-09-10 Wyeth Thioamide derivatives as progesterone receptor modulators
ATE409699T1 (de) * 2004-04-08 2008-10-15 Wyeth Corp Verfahren zur minimierung von thioamidverunreinigungen
CN1946716B (zh) * 2004-04-27 2011-12-21 惠氏公司 含有氰基吡咯的环状氨基甲酸酯和硫代氨基甲酸酯联芳基以及其制备方法
CA2575737C (en) * 2004-08-13 2013-09-24 Wyeth Tanaproget derivatives, metabolites, and uses thereof
US7399766B2 (en) * 2004-08-18 2008-07-15 Parion Sciences, Inc. Soluble amide & ester pyrazinoylguanidine sodium channel blockers
CA2575803A1 (en) * 2004-08-20 2006-03-23 Wyeth Progesterone receptor structure
DE602006012972D1 (de) * 2005-04-28 2010-04-29 Wyeth Corp Mikronisierte tanaproget zusammensetzungen und verfahren zu ihrer herstellung
AU2011226814B2 (en) * 2005-04-28 2013-06-13 Wyeth Llc Micronized tanaproget, compositions, and methods of preparing the same
AU2011203520B2 (en) * 2005-04-28 2012-06-14 Wyeth Micronized tanaproget and compostions containing same
JP5149161B2 (ja) * 2005-04-28 2013-02-20 ワイス・エルエルシー ミクロ化タナプロゲットを含む組成物
PE20061322A1 (es) * 2005-04-28 2006-12-28 Wyeth Corp Forma purificada de tanaproget
MX2007013469A (es) * 2005-04-28 2008-01-22 Wyeth Corp Forma ii polimorfa de tanaproget.
BRPI0610431A2 (pt) * 2005-04-28 2012-10-23 Wyeth Corp composição farmacêutica, processo para preparar uma composição, cápsula, e, kit farmacêutico
TW200716137A (en) * 2005-06-09 2007-05-01 Wyeth Corp Tanaproget compositions containing ethinyl estradiol
AU2007338102A1 (en) * 2006-12-22 2008-07-03 F. Hoffmann-La Roche Ag Processes for the preparation of (3R, 4R) -N- (4 -chlorophenyl) -1- (2, 2-difluoroethyl) -N' - [2-fluoro-4- (2-oxo-1 (2H) -pyridinyl) phenyl] -3, 4-pyrrolidinedicarboxamide
EA201070715A1 (ru) 2007-12-20 2011-02-28 Тева Вимен'С Хелс, Инк. Режимы дозирования, фармацевтические композиции и упаковки для экстренной контрацепции
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
JP2013504531A (ja) * 2009-09-11 2013-02-07 バイエル・ファルマ・アクチェンゲゼルシャフト 抗癌薬としての置換（ヘテロアリールメチル）チオヒダントイン
HUE033581T2 (hu) 2010-06-10 2017-12-28 Seragon Pharmaceuticals Inc Ösztrogén receptor modulátorok és alkalmazásaik
SG11201403002RA (en) 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
US20170014174A1 (en) * 2015-07-17 2017-01-19 Candela Corporation Cryogenic Cylinder

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2002A (en) * 1841-03-12 Tor and planter for plowing
US2003A (en) * 1841-03-12 Improvement in horizontal windivhlls
WO1985000519A1 (en) * 1983-07-29 1985-02-14 Duke University Method of treating androgen-related disorders
GB2310660A (en) * 1996-03-01 1997-09-03 Merck & Co Inc Benzoxazinone oxytocin receptor antagonists
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6326392B1 (en) * 1997-11-06 2001-12-04 American Home Products Corporation Anti-estrogen plus progestin containing oral contraceptives
DE59913181D1 (de) * 1998-10-23 2006-04-27 Aventis Pharma Sa Zubereitungen zur topischen applikation von antiandrogen wirksamen substanzen
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6509334B1 (en) * 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6407101B1 (en) * 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001030356A1 (fr) * 1999-10-25 2001-05-03 Laboratoire Theramex Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20010034340A1 (en) * 2000-03-20 2001-10-25 American Home Products Corporation Hormone replacement therapy
UA73119C2 (en) 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
FR2814074B1 (fr) * 2000-09-15 2003-03-07 Theramex Nouvelles compositions estro-progestatives topiques a effet systemique

Also Published As

Publication number Publication date
ECSP055576A (es) 2005-04-18
CN1662241A (zh) 2005-08-31
KR20050013247A (ko) 2005-02-03
BR0312024A (pt) 2005-03-22
JP2005535624A (ja) 2005-11-24
IL165396A0 (en) 2006-01-15
CO5680438A2 (es) 2006-09-29
MXPA04012421A (es) 2005-04-19
NO20045216L (no) 2005-01-24
CA2489847A1 (en) 2003-12-31
US7192956B2 (en) 2007-03-20
WO2004000801A3 (en) 2004-03-25
WO2004000801A2 (en) 2003-12-31
TW200404548A (en) 2004-04-01
RU2005101638A (ru) 2006-01-20
AU2003247608A1 (en) 2004-01-06
AR040333A1 (es) 2005-03-30
US20040006060A1 (en) 2004-01-08
EP1515725A2 (en) 2005-03-23
EP1515725A4 (en) 2005-09-21
ZA200410411B (en) 2007-06-27

Similar Documents

Publication Publication Date Title
ECSP055576A (es) Uso de derivados de ciclotiocarbamato en el tratamiento de las condiciones relacionadas con hormonas
ECSP055574A (es) Uso de derivados de tio-oxindol en el tratamiento de condiciones relacionadas con hormonas.
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
CR7420A (es) Composiciones farmaceuticas que comprenden uno o varios esteroides, uno o varios componentes de tetrahiidrofolatos y vitamina b12
ATE497745T1 (de) Zusammensetzungen mit verzögerter freisetzung mit progesteron-rezeptormodulatoren
AR059174A1 (es) Formas farmaceuticas en forma de pelicula para usar en la cavidad bucal (obleas)
UY29182A1 (es) "derivados de bencenosulfonamidas sustituídas, composiciones que las contienen, procedimientos de preparación y aplicaciones"
UY29087A1 (es) Derivados de adamantilo, composiciones farmaceuticas que los contienen, procesos para su preparacion y uso terapeutico
ECSP077233A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
ECSP077236A (es) Moduladores del receptor de progesterona que comprenden los derivados del pirrol-oxindol y los usos de los mismos
HN2008000621A (es) Metodo para la anticopcepcion hormonal preventiva bajo demanda
ECSP077323A (es) Nuevos derivados de sulfonamida como moduladores del receptor de glucocorticoides para el tratamiento de enfermedades inflamatorias
UA86957C2 (ru) Производные азепиноиндола в качестве фармацевтического средства
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
PA8583401A1 (es) Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf)
ECSP066999A (es) Envase farmacéutico para anticoncepción hormonal de régimen extendido flexible
CO2021000041A2 (es) Degradadores selectivos del receptor de estrógeno
AR059423A1 (es) Administracion oral de agentes terapeuticos usando agonistas de uniones impermeables
ES2190205T3 (es) Combinacion para el tratamiento de la dependencia del alcohol que contiene un antagonista opioide y un modulador del complejo receptor de nmda.
EA200901393A1 (ru) Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат
PE20060275A1 (es) Composicion farmaceutica que contiene progestina y estrogeno para el tratamiento de trastorno disforico premenstrual
UY29701A1 (es) Formulaciones líquidas para la administración controlada de derivados de bencisoxazol
CR11584A (es) Derivados de oxindol sustituidos y uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina
CR9627A (es) Cyanopyrrole-sulfonamide progesterone receptor modulators and uses thereof
SV2011003896A (es) Pirrolidinas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)